Fetal alloimmune thrombocytopenia: consensus and controversy

Area of Science:

• Obstetrics and Gynecology
• Neonatology
• Immunology

Background:

• Fetal and neonatal alloimmune thrombocytopenia (AIT) poses significant risks, including antenatal intracranial hemorrhage (ICH), potentially worsening in subsequent pregnancies.
• Advances in antenatal diagnosis and treatment have been made for AIT.

Purpose of the Study:

• To review current knowledge on the laboratory diagnosis, natural history, and management of fetal AIT during pregnancy.
• To analyze discrepancies in outcomes between European and US studies and identify contributing factors.

Main Methods:

• Review of existing literature on laboratory diagnosis of AIT in pregnancy.
• Analysis of management strategies and outcomes in fetal AIT from European and US cohorts.
• Examination of factors contributing to outcome variations, including population differences, management protocols, and treatment response definitions.

Main Results:

• Intravenous immune globulin (IVIG) demonstrates efficacy in elevating fetal platelet counts.
• IVIG treatment is associated with a reduced incidence of fetal intracranial hemorrhage (ICH).
• Discrepancies in AIT management outcomes exist between Europe and the United States, influenced by population, treatment, and response definitions.

Conclusions:

• IVIG is an effective treatment for increasing fetal platelet counts and preventing ICH in alloimmune thrombocytopenia.
• Understanding and addressing discrepancies in management and outcome definitions are crucial for optimizing fetal AIT care globally.